Bioxcel Therapeutics, Inc. · NASDAQ:BTAI

Bioxcel Therapeutics — Investor Presentation (September 2022)

7 slides from Bioxcel Therapeutics's investor presentation, Sep 12, 2022

  1. Slide 1: AI-Driven Drug Development in Neuroscience and Immuno-oncology

    ® BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com September 2022 AI-Driven Drug Development in Neuroscience and Immuno-oncology NASDAQ: BTAI

  2. Slide 2: Forward-looking statements

    This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.Forward-looking statements in this presentation include but are not limited to: statements regarding BioXcel Therapeutics’ expected timing of, and data results from, tri

  3. Slide 3: Potential Market-Changing Product & Current Pipeline

    Compound Indication/Proposed Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed Neuroscience BXCL501 At-home acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults Acute treatment of agitation associated with Alzheimer’s disease* Adjunctive

  4. Slide 4: Near-Term Catalysts & Key Events

    Near-Term Catalysts & Key Events NEUROSCIENCE: BXCL501 Timeframe IGALMI™ U.S. Commercial Launch July 2022 Alzheimer’s Disease: TRANQUILITY III • Expected study initiation 2H 2022 Bipolar Disorders or Schizophrenia (at-home use): SERENITY III • Expected study initiation 2H 2022 Alzheimer’s Disease: T

  5. Slide 5: • Optimize R&D economics • Shorten development timelines • Achieve higher probability of success

    • Optimize R&D economics • Shorten development timelines • Achieve higher probability of success * all 3 driven by comprehensive AI plan • Proprietary EvolverAI™ technology platform • BXCL501 – IND acceptance to IGALMI™ approval in 3.5 yrs. - 3 upcoming Phase 3 trials • BXCL701 – Human POC establish

  6. Slide 6: Significant Market Opportunity: Agitation in Bipolar Disorders & Schizophrenia

    Significant Market Opportunity: Agitation in Bipolar Disorders & Schizophrenia 15 1. Wu, 2006, NAMI 2. NIMH- Prevalence of bipolar disorder in adults. November 2017. Accessed June 24, 2021. https://www.hcp.med.harvard.edu/ncs/ftpdir/NCS-R_12- month_Prevalence_Estimates.pdf 3. Data on File 4. inVibe

  7. Slide 7: Significant Market Opportunity: Agitation in Bipolar Disorders & Schizophrenia

    Significant Market Opportunity: Agitation in Bipolar Disorders & Schizophrenia 23 1. Wu, 2006, NAMI 2. NIMH- Prevalence of bipolar disorder in adults. November 2017. Accessed June 24, 2021. https://www.hcp.med.harvard.edu/ncs/ftpdir/NCS-R_12- month_Prevalence_Estimates.pdf 3. Data on File 4. inVibe

BioXcel Therapeutics — Investor Presentation (September 2022) on 6ix